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The colony-stimulating factor-1 receptor (CSF-1R) kinase regulates tissue macrophage homeostasis, osteoclastogenesis, and Paneth cell development. However, recent studies in mice have revealed that CSF-1R signaling directly controls the development and maintenance of microglia, and cell autonomously regulates neuronal differentiation and survival. While the CSF-1R-cognate ligands, CSF-1 and interleukin-34 (IL-34) compete for binding to the CSF-1R, they are expressed in a largely non-overlapping manner by mature neurons. The recent identification of a dominantly inherited, adult-onset, progressive dementia associated with inactivating mutations in the CSF-1R highlights the importance of CSF-1R signaling in the brain. We review the roles of the CSF-1R and its ligands in microglial and neural development and function, and their relevance to our understanding of neurodegenerative disease.
CSF-1R and CSF-1R Ligands and their Expression Patterns in Brain
CSF-1R is a class III receptor tyrosine kinase activated by two homodimeric glycoprotein ligands, CSF-1 [1] and IL-34) [2] , that exhibit low primary sequence homology but share a short chain four /-helical bundle cytokine fold and interact with overlapping regions of the CSF-1R (reviewed in [3] ). CSF-1 signals exclusively through the CSF-1R, while IL-34 interacts with at least one additional receptor, receptor protein tyrosine phosphatase-z (PTP-z), which is coexpressed with the CSF-1R on neural progenitor cells [4] (Box 1). In myeloid cells, activation of the CSF-1R by CSF-1 or IL-34 leads to comparable biological outcomes [2, 5] . However, in vivo the two endogenous CSF-1R ligands exhibit different spatiotemporal patterns of expression, and play complementary roles in controlling the development, maintenance, and activity of target cell types [5] [6] [7] [8] .
CSF-1R Expression in Brain
While the CSF-1R is expressed on all microglia [9,10], there are contradictory reports concerning its expression in the neuronal lineage. Initial studies, using several CSF-1R antibodies and in situ hybridization, reported that in adult brain CSF-1R was expressed in several neuronal subpopulations and that neuronal expression was increased following ischemic cerebral cortical injury [11, 12] . However, in a recent study, none of six commercial anti-CSF-1R antibodies tested was specific, as demonstrated by their staining of Csf1r-deficient brain [13] , calling into question the validity of the immunohistochemical data. Furthermore, several independent groups [14] [15] [16] were unable to detect neuronal expression using the same Csf1r-EGFP reporter mouse [17] . However, using a different Csf1r-EGFP reporter mouse [18] with GFP staining, corroborated by in situ hybridization, several of the findings of Wang et al. [11] were reproduced, including expression by a small fraction of hippocampal neurons and increased expression in injured Trends CSF-1R is a receptor tyrosine kinase with two cognate ligands, CSF-1 and IL-34, that are expressed in largely non-overlapping areas of the CNS and that regulate microglial proliferation, and survival.
The CSF-1R is also expressed in neural progenitor cells and regulates their survival, proliferation and neuronal differentiation.
Upregulation of CSF-1R expression in injured neurons promotes survival.
Mutations in the CSF1R gene lead to an autosomal dominant, neurodegenerative disorder known as adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP).
The Csf1r +/À mouse is a validated model for testing therapeutic strategies for ALSP.
CSF-1R ligands and inhibitors are potential modulators of several neurological diseases including Alzheimer's disease, globoid cell leukodystrophy (Krabbe's disease), Charcot-MarieTooth disease, multiple sclerosis, and glioma.
